Clinical Trial

Find HDV and Determine Its Status in Turkey

Study acronym: SITUHDVATION
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 12, 2024 (before its estimated February 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The aim of these study to determine the prevalence of hepatitis Delta virus (HDV) infections and the prognosis of HDV patients in Turkey's southeast. The investigators intend to arrange training sessions for 250 family physicians in Diyarbakir, Batman, Mardin, and Sanliurfa in order to determine those goals. The investigators will talk about diagnosing hepatitis B virus (HBV), HDV, hepatitis C virus (HCV), and Human Immunodeficiency virus (HIV) infections during these events. To ensure that patients with simultaneous HDV infection are evaluated for HIV/HCV and to detect liver fibrosis with a non-invasive method.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-01-31; most recent amendment 2024-08-08.
Status change: Not Yet Recruiting → Recruiting 2024-04-20
Trial Details
NCT Number NCT06248580
Lead Sponsor Yaşar Bayındır, MD
Collaborators: SOUTHEAST NEUROLOGY AND INFECTIOUS DISEASES SOCIETY, Gilead Sciences
Conditions Chronic Hepatitis D Infection, Fibrosis, Liver, Hepatocellular Carcinoma, Cirrhosis, Liver, Transmission Vertical
Enrollment 20,000 participants
Start Date 2024-03-11
Primary Completion 2025-02-01 (estimated)
Study Completion 2025-03-01 (estimated)
Updated on ClinicalTrials.gov 2024-08-12